Back to Journals » OncoTargets and Therapy » Volume 9

Bilateral breast adenocarcinomas with EML4ALK fusion in a patient with multiple metastases successfully treated with crizotinib: is lung the primary site?

Authors Liu C, Ding L, Sun B, Wu S

Received 20 January 2016

Accepted for publication 8 April 2016

Published 16 June 2016 Volume 2016:9 Pages 3589—3593

DOI https://doi.org/10.2147/OTT.S104583

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Triparna Sen

Peer reviewer comments 3

Editor who approved publication: Professor Min Li


Chao Liu,1,2 Lijuan Ding,2 Bing Sun,2 Shikai Wu1,2

1Department of Radiation Oncology, 307 Hospital of People’s Liberation Army, 307 Clinical College, Anhui Medical University, 2Department of Radiation Oncology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, People’s Republic of China

Abstract: Breast metastases from non-mammary cancers are rare, especially when they appear synchronously. Clinically, it is vitally important to accurately diagnose these patients, as this will directly influence their treatment and survival. We present a very rare and complex case of bilateral breast adenocarcinomas with an EML4ALK fusion, which was diagnosed as bilateral breast metastases of non-small-cell lung cancer by immunohistochemistry and comprehensive genomic investigation. The patient was successfully treated with an ALK inhibitor (crizotinib); symptoms improved quickly after initiation of crizotinib therapy, and a partial response was observed after 3 months. The experience of diagnosis and treatment of this case indicates the importance and necessity of genomic investigations in such patients, and suggests that we need to consider the rare possibility of this kind of metastasis in order to provide optimal treatment.

Keywords: ALK inhibitor, metastatic adenocarcinoma, gene expression profiling

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]